30 November 2020 - ARS Pharmaceuticals announced today that the EMA has accepted a marketing authorisation application submission for review of Neffy (ARS-1; epinephrine nasal spray) an epinephrine nasal spray for the emergency treatment of severe allergic reactions, including anaphylaxis. 

This follows ARS' recent announcement of an exclusive licensing agreement with Recordati for commercialization of Neffy in 93 countries including those in the European Union. 

Neffy is the trademark name established in the U.S.; the European product name has not yet been established.

Read ARS Pharmaceuticals press release